- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Janssen’s IMBRUVICA® receives recommendation to broaden treatment application for CLL patients
3 May 2016 • Author: Mandy Parrett, Editorial Assistant
IMBRUVICA® is currently approved for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) and adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, as well as other circumstances for patients demonstrating unsuitability for chemo-immunotherapy.
IMBRUVICA® new application
Following consideration of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), however, the recommended application could see ibrutinib being used as a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
CLL is generally a slow-growing blood cancer of the white blood cells called B-lymphocytes; the median age of diagnosis being 72 years and incidence rates among men and women in Europe being approximately 5.87 and 4.01 cases per 100,000 persons per year, respectively. The chronic disease often sees patients being faced with ever decreasing treatment options, so this wider first time, single agent application could provide new hope for patients.
The ‘Positive Opinion’ of the CHMP was based on the results of a clinical trial published in The New England Journal of Medicine (NEJM) – Phase 3, randomised, open-label RESONATE™-2 (PCYC-1115) – which showed ibrutinib provided significant improvement in all efficacy endpoints versus chemotherapy comparator Chlorambucil in newly diagnosed CLL patients aged 65 and over.
“Janssen is proud to be leading the charge with our ongoing efforts to transform the treatment experience for patients with difficult to treat blood cancers, such as CLL,” said Jane Griffiths, Company Group Chairman, Janssen Europe, Middle East and Africa. “Ibrutinib continues to demonstrate impressive clinical results, and the data on which this recommendation is based once again highlights its potential to deliver improved patient outcomes for suitable patients.”
This regulatory milestone follows the decision by the U.S. Food and Drug Administration in March 2016, to approve the expanded use of ibrutinib capsules for treatment-naïve patients with CLL.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics